Amy Abernethy, a director of CM Life Sciences III Inc., recently acquired 200,000 shares of the company. The buys took place at $0.00 per share, on December 17, 2021. Abernethy now owns 200,000 shares of the company. Abernethy operates out of Cambridge, MA. Some additional info was provided as follows:
Immediately prior to the consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of the Issuer's Class B Common Stock automatically converted into shares of Class A Common Stock on a one-for-
one basis (the "Conversion").
Immediately following the Conversion but prior to Closing, the Class A Common Stock was reclassified as Common Stock.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever CM Life Sciences III Inc. makes a similar move, sign up!
